Moove It’s Health Index uses data to reveal the cities with the most developed healthtech ecosystems in the world and the software consulting firm recently ranked Vancouver third among Canadian cities for advancement of their healthtech sectors.
Supporting Vancouver’s ranking as a global city leading the technological advancement of healthcare, the Healthcare Technology Report has announced their list of the Top 25 Healthcare Technology Leaders of Vancouver for 2022.
For Vancouver, both funding and employment scored particularly high, and it’s no wonder why, given the awardees on this year’s list and the revolutionary companies they represent.
Across a range of specialties, from pharmaceuticals to nanotechnology, genomics, and data analytics, among many others, these companies and their leaders are producing innovations that are having significant impacts on patients, their families, and physicians in Vancouver and beyond.
Among the list of distinguished leaders is Precision NanoSystems CEO James Taylor, Semios CEO Michael Gilbert, and Acuitas Therapeutics CEO Thomas Madden.
Taylor has grown Precision NanoSystems to become the leading technology provider for the development of nanomedicines and has expanded its global headquarters in Vancouver with a 75,000-square-foot Genetic Medicine GMP Biomanufacturing Center facility.
Meanwhile, Gilbert has grown Semios into a leader in the agtech sector, helping farmers use data to optimize every acre and predict, identify, and prevent pest and disease pressure. Gilbert recently announced he is stepping down at the end of this month after leading the company for 13 years.
And Madden is a world-renowned expert in the area of nanotechnology and has guided his company to its position as a global leader through the development and application of lipid nanoparticle (LNP) technology. Acuitas Therapeutics recently entered into an agreement with Pfizer to license their LNP technology.
Check out the complete list of Top 25 Healthcare Technology Leaders of Vancouver for 2022 here.
Leave a Reply